XXY-2A1	
    			    			
                CRICKi024-B            
            
        General
| Cell Line | |
| hPSCreg name | CRICKi024-B | 
| Cite as: | CRICKi024-B (RRID:CVCL_E3TS) | 
| Alternative name(s) | 
	XXY-2A1	 | 
| Cell line type | Human induced pluripotent stem cell (hiPSC) | 
| Similar lines | No similar lines found. | 
| Last update | 23rd August 2025 | 
| User feedback | |
| Provider | |
| Generator | The Francis Crick Institute Limited (CRICK) | 
| Owner | The Francis Crick Institute Limited (CRICK) | 
| Distributors | |
| Derivation country | United Kingdom | 
| External Databases | |
| BioSamples | SAMEA116060738 | 
| Cellosaurus | CVCL_E3TS | 
| General Information | |
| * Is the cell line readily obtainable for third parties? | Yes Research use: allowed Clinical use: not allowed Commercial use: not allowed | 
Donor Information
| General Donor Information | |
| Sex | male | 
| Age of donor (at collection) | fetal | 
| Ethnicity | Caucasian | 
| Phenotype and Disease related information (Donor) | |
| Diseases | A disease was diagnosed. | 
| Is the medical history available upon request? | NO | 
| Is clinical information available? | NO | 
| Other Genotyping (Donor) | |
| Is there genome-wide genotyping or functional data available? | No | 
| Donor Relations | |
| Other cell lines of this donor | |
| External Databases (Donor) | |
| BioSamples | SAMEA7485351 | 
Ethics
| Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? | Yes | 
| Was the consent voluntarily given? | Yes | 
| Has the donor been informed that participation will not directly influence their personal treatment? | Yes | 
| Can you provide us with a copy of the Donor Information Sheet provided to the donor? | No | 
| Do you (Depositor/Provider) hold the original Donor Consent Form? | No | 
| If you do not hold the Donor Consent Form, do you know who does? | Yes | 
| Alternatives to consent are available? | Yes | 
| Alternatives to consent | https://www.coriell.org/1/NIGMS | 
| Alternative consent approval number | |
| Is there other documentation provided to the donor for consenting purposes? | No | 
| Confirm that consent was obtained by a qualified professional | Yes | 
| Has the donor agreed to be re-contacted? | Unknown | 
| Has the donor been informed about how her/his data will be protected? | Yes | 
| Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. | anonymised | 
| Does consent explicitly allow the derivation of pluripotent stem cells? | No | 
| * Does consent expressly prevent the derivation of pluripotent stem cells? | No | 
| * Does consent pertain to a specific research project? | No | 
| Does consent permit unforeseen future research, without further consent? | No | 
| Does the consent permit uses of donated embryo/tissue or derived cell line intended for clinical treatment or human applications? | Yes | 
| Does consent expressly prevent development of commercial products? | Yes | 
| Does consent expressly prevent financial gain from any use of the donated embryo/tissue, including any product made from it? | Yes | 
| Does consent expressly permit storage of donated embryo/tissue for an unlimited time? | No | 
| Does consent expressly permit storage of cells derived from the donated embryo/tissue for an unlimited time? | No | 
| Does consent prevent the DONATED BIOSAMPLE from being made available to researchers anywhere in the world? | No | 
| Does consent prevent CELLS DERIVED FROM THE DONATED BIOSAMPLE from being made available to researchers anywhere in the world? | No | 
| Does consent permit research by | |
| an academic institution? | Yes | 
| a public organisation? | Yes | 
| a non-profit company? | Yes | 
| a for-profit corporation? | Yes | 
| Does consent expressly permit collection of genetic information? | Yes | 
| Does consent expressly permit storage of genetic information? | Yes | 
| Does consent prevent dissemination of genetic information? | No | 
| Has the donor been informed that their donated biosample or derived cells may be tested for the presence of microbiological agents / pathogens? | No | 
| Has the donor consented to receive information discovered during use of donated embryo/tissue that has significant health implications for the donor? | No | 
| How may genetic information associated with the cell line be accessed? | Controlled Access | 
| Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? | No | 
| Does the consent anticipate that the donor will be notified of results or outcomes of any research involving the donated samples or derived cells? | No | 
| Does the consent permit the donor, upon withdrawal of consent, to stop the use of the derived cell line(s) that have already been created from donated samples? | Yes | 
| Does the consent permit the donor, upon withdrawal of consent, to stop delivery or use of information and data about the donor? | Yes | 
| Does consent permit access to medical records of the donor? | No | 
| Does consent permit access to any other source of information about the clinical treatment or health of the donor? | No | 
| Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? | Yes | 
| Name of accrediting authority involved? | Fibroblast GM03102 were obtained from the NIGMS Human Genetic Cell Repository at the Coriell Institute for Medical Research,USA. | 
| Approval number | |
| Is there an MTA available for the cell line? | Yes | 
| For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? | Thermofisher Scientific | 
| Are you aware of any constraints on the use or distribution of the cell line from the owner or any parties identified in the query above? | No | 
hIPSC Derivation
| General | |
| Source cell line name | GM03102 Other names Derived from same source line (potentially other lot and donor, see below):
							
							 | 
| Source cell type | Synonyms 
 | 
| Source cell line lot number | GM03102 Derived from same source line lot:
									
									 | 
| Age of donor (at collection) | fetal | 
| Source cell line vendor | Coriell | 
| Reprogramming method | |
| Vector type | Non-integrating | 
| Vector | Sendai virus | 
| Genes | |
| Is reprogramming vector detectable? | No | 
| Methods used | 
	RT-PCR	 | 
| Notes on reprogramming vector detection | using qRT-PCR Taqman probes | 
| Files and images showing reprogramming vector expressed or silenced | |
| Vector free reprogramming | |
| Other | |
| Derived under xeno-free conditions | No | 
| Derived under GMP? | No | 
| Available as clinical grade? | No | 
Culture Conditions
| Surface coating | Vitronectin | 
| Feeder cells | No | 
| Passage method | Enzyme-free cell dissociation 
											versene										 | 
| O2 Concentration | 21 % | 
| CO2 Concentration | 5 % | 
| Medium | Other medium: 
			Base medium: STEMFLEX			 Main protein source: Serum concentration: % | 
| Has Rock inhibitor (Y27632) been used at passage previously with this cell line? | No | 
| Has Rock inhibitor (Y27632) been used at cryo previously with this cell line? | No | 
| Has Rock inhibitor (Y27632) been used at thaw previously with this cell line? | Yes | 
Characterisation
Analysis of Undifferentiated Cells
| Marker | Expressed | Immunostaining | RT-PCR | Flow Cytometry | Enzymatic Assay | Expression Profiles | 
| POU5F1 (OCT-4) | Yes |  | ||||
| NANOG | Yes |  | ||||
| SOX2 | Yes |  | 
Morphology pictures
Differentiation Potency
Genotyping
| Karyotyping (Cell Line) | |
| Has the cell line karyotype been analysed? | Yes | 
| Other Genotyping (Cell Line) | |

Login to share your feedback, experiences or results with the research community.